AMENDMENTS TO THE CLAIMS

1. (Original) A process of isolating pravastatin, comprising the steps of (1) adding an ammonium sulfate into a first solution containing the (HMG)-CoA reductase inhibitor to produce a precipitation; (2) isolating the precipitation; (3) dissolving the precipitation with a polar solvent to produce a second solution; (4) adjusting the pH of the second solution to about pH 4 to about PH6; and (5) extracting the second solution with an water immiscible solvent to isolate the (HMG)-CoA reductase inhibitor.

2. (Original) The process of Claim 1, wherein the (HMG)-CoA reductase inhibitor is selected from pravastatin, compactin and lovastatin.

3. (Original) The process of Claim 2, wherein the (HMG)-CoA reductase inhibitor is pravastatin.

4. (Original) The process of Claim 1, wherein the first solution of Step (1) is a microbial fermentation broth.

5. (Currently Amended) The process of Claim 4, wherein the microbial fermentation broth is derived from a microorganism capable of producing the (HMG)-CoA reductase inhibitor, said microorganism is selected form *Streptomyces roseochrornogenus, Actinomadura, Aspergillus, Monascus, Penicillium, Paecilomyces, Hypomyces, Phoma, Pleurotus, Doratmyces, Eupenicillium, Gymnoaxus, Trichoderma,* ~~*YS-44442* of Claim 1, *YS-45494* of claim 2~~ YS-44442 of *Saccharothrix*, YS-45494 of *Saccharothrix*, and the mutants thereof.

6. (Original) The process of Claim 1, wherein the ammonium sulfate of Step (1) is added into the first solution in an amount of 30 to 60% (w/v) of the first solution.

7. (Original) The process of Claim 6, wherein the ammonium sulfate is added to be saturated in the first solution.

8. (Original) The process of Claim 1, wherein the water immiscible solvent of Step (5) is an organic solvent.

9. (Original) The process of Claim 8, wherein the organic solvent is selected from ethyl acetate, acetone, toluene, dicholoromethane and isopropyl acetate.

10. (Original) The process of Claim 9, wherein the organic solvent is ethyl acetate.

11. (Original) The process of Claim 1, further comprising a step of reacting the isolated (HMG)-CoA reductase inhibitor with an organic or inorganic cation source to generate a salt form of the inhibitor.

12. (Original) The process of claim 11, wherein the cation source is a sodium source.

13. (Original) The process of Claim 12, wherein the sodium source is selected form NaOH, NA_2CO_3 sodium acetate (anhydrous) and sodium-2-ethyl hexanoate.